Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Лечебное дело
2015 / N 4

Генетический полиморфизм CYP2C19 – предиктор клинической эффективности ингибиторов протонной помпы (библиография)
М.В. Леонова

1. Lee S.-J. Clinical application of CYP2C19 pharmacogenetics toward more personalized medicine // Front. Genet. 2013. V. 3. P. 1–7.
2. Kuo C.H., Lu C.Y., Shih H.Y. et al. CYP2C19 polymorphism influences Helicobacter pylori eradication // World J. Gastroenterol. 2014. V. 20. P. 16029–16036.
3. Goldstein J.A., Ishizaki T., Chiba K. et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations // Pharmacogenetics. 1997. V. 7. P. 59–64.
4. Мирзаев К.Б., Сычев Д.А., Андреев Д.А. Этнические особенности в российской федерации полиморфизма гена cyp2с19, ассоциированного с нарушением ответа на клопидогрел // Мол. мед. 2014. № 1. C. 13–21.
5. Redal M.A., Belloso W.H., Scibona P. et al. Pharmacogenomics in Gastroenterology // Clinical Applications of Pharmacogenetics / Ed. by Sanoudou D. Rijeka: InTech, 2012. P. 201–222.
6. Kusano M., Kuribayashi S., Kawamura O. et al. A Review of the management of gastric acid-related diseases: focus on rabeprazole // Clinical Medicine Insights: Gastroenterology. 2011. V. 3. P. 31–43.
7. Kromer W., Kruger U., Huber R. et al. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates // Pharmacology. 1998. V. 56. P. 57–70.
8. Kirchheiner J., Glatt S., Fuhr U. et al. Relative potency of proton-pump inhibitors – comparison of effects on intragastric pH // Eur. J. Clin. Pharmacol. 2009. V. 65. P. 19–31.
9. Pantoflickova D., Dorta G., Ravic M. et al. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors // Aliment. Pharmacol. Ther. 2003. V. 17. P. 1507–1514.
10. Sugimoto M., Shirai N., Nishino M. et al. Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype // Aliment. Pharmacol. Ther. 2012. V. 36. P. 627–634.
11. Roche V.F. The chemically elegant proton pump inhibitors // Am. J. Pharm. Educ. 2006. V. 70. P. 1–11.
12. Horn J. Review article: relationship between the metabolism and efficacy of proton pump inhibitors – focus on rabeprazole // Aliment. Pharmacol. Ther. 2004. V. 20. P. 11–19.
13. Klotz U., Schwab M., Treiber G. CYP2C19 polymorphism and proton pump inhibitors // Basic. Clin. Pharmacol. Toxicol. 2004. V. 95. P. 2–8.
14. Sugimoto M., Furuta T. Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype // World J. Gastroenterol. 2014. V. 20. P. 6400–6411.
15. Sahara S., Sugimoto M., Uotani T. et al. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole // Aliment. Pharmacol. Ther. 2013. V. 38. P. 1129–1137.
16. Li-Wan-Po A., Girard T., Farndon P. et al. Рharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17 // Br. J. Clin. Pharmacol. 2010. V. 69. P. 222–230.
17. Sim S.C., Risinger C., Dahl M-L. et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants // Clin. Pharmacol. Ther. 2006. V. 79. P. 103–113.
18. Malfertheiner P., Megraud F., O’Morain C.A., et al; European Helicobacter Study Group. Management of helicobacter pylori infection – the Maastricht IV Florence Consensus Report // Gut. 2012. V. 61. P. 646–664.
19. Kuo C.H., Kuo F.C., Hu H.M. et al. The optimal first-line therapy of Helicobacter pylori infection in year 2012 // Gastroenterol. Res. Pract. 2012. P. 168361. doi:10.1155/2012/168361
20. Graham D.Y., Shiotani A. New Concepts of Resistance in the Treatment of Helicobacter pylori Infections // Nat. Clin. Pract. Gastroenterol. Hepatol. 2008. V. 5. P. 321–331.
21. Furuta T., Shirai N., Takashima M. et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin // Clin. Pharmacol. Ther. 2001. V. 69. P. 158–168.
22. Furuta T., Ohashi K., Kamata T. et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer // Ann. Intern. Med. 1998. V. 129. P. 1027–1030.
23. Chaudhry A.S., Kochhar R., Kohli K.K. Genetic polymorphism of CYP2C19 & therapeutic response to proton pump inhibitors // Indian J. Med. Res. 2008. V. 127. P. 521–530.
24. Padol S., Yuan Y., Thabane M. et al. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: а meta-analysis // Am. J. Gastroenterol. 2006. V. 101. P. 1467–1475.
25. Zhao F., Wang J., Yang Y. et al. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis // Helicobacter. 2008. V. 13. P. 532–541.
26. McNicholl A.G., Linares P.M., Nyssen O.P. et al. Meta-analysis: еsomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection // Aliment. Pharmacol. Ther. 2012. V. 36. P. 414–425.
27. Tamura T., Kurata M., Inoue E S. et al. Improvements in Helicobacter pylori eradication rates through clinical CYP2C19 genotyping // Nagoya J. Med. Sci. 2011. V. 73. P. 25–31.
28. Furuta T., Shirai N., Kodaira M. et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori // Clin. Pharmacol. Ther. 2007. V. 81. P. 521–528.
29. Furuta T., Shirai N., Sugimoto M. et al. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies // Drug Metab. Pharmacokinet. 2005. V. 20. P. 153–167.
30. Sugimoto M., Furuta T., Shirai N. et al. Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes // Clin. Pharmacol. Ther. 2005. V. 77. P. 302–311.
31. Kawamura M., Ohara S., Koike T. et al.; Study Group of GERD. The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism // Aliment. Pharmacol. Ther. 2003. V. 17. P. 965–973.
32. Lee Y.C., Lin J.T., Wang H.P. et al. Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease // J. Gastroenterol. Hepatol. 2007. V. 22. P. 1286–1292.
33. Thomson A.B., Sauve M.D., Kasam N., Kamitakahara H. Safety of long-term use of protein pump inhibitors // World J. Gastroenterol. 2010. V. 16. P. 2323–2330.
34. Hu Y.M., Mei Q., Xu X.H. et al. Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese // World J. Gastroenterol. 2006. V. 12. P. 4750–4753.
35. Hagymási K., Müllner K., Herszényi L., Tulassay Z. Update on the Pharmacogenomics of Proton Pump Inhibitors // Pharmacogenomics. 2011. V. 12. P. 873–888.
36. Lehmann D.F., Medicis J.J., Franklin P.D. Polymorphisms and the pocketbook: the cost-effectiveness of cytochrome P450 2C19 genotyping in the eradication of Helicobacter pylori infection associated with duodenal ulcer // J. Clin. Pharmacol. 2003. V. 43. P. 1316–1323.
  

[ Содержание выпуска N 4 | Выпуски журнала | Список журналов ]